Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy

Soo Min Jang^a Grayson Hough^b Bruce A. Mueller^c

^aDepartment of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA;

^bCidara Therapeutics, San Diego, CA, USA; ^cDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA

Keywords

Rezafungin · Drug clearance · Continuous venovenous hemofiltration · Ex vivo

Abstract

Background/Aims: To determine adsorption and transmembrane clearances (CL_{TM}) of rezafungin, a novel long-acting echinocandin, in continuous venovenous hemofiltration (CVVH). **Methods:** A validated ex vivo bovine blood CVVH model using polysulfone and AN69 hemodiafilters was used to evaluate urea and rezafungin CL_{TM} at 3 different ultrafiltrate flow rates. Rezafungin adsorption to the CRRT apparatus was determined for each hemodiafilter. **Results:** The sieving coefficient (S_C) from CVVH with 3 different ultrafiltrate flow rates was 0 for both HF1400 and Multiflow-150 hemodiafilters, while urea S_C was approximately 1 at all flow rates. Hemodiafilter type and ultrafiltrate flow rate did not

influence CL_{TM} . Rezafungin adsorption to the CVVH apparatus was not observed for either hemodiafilter. **Conclusion:** Rezafungin is not removed by CVVH by membrane adsorption or via CL_{TM} . Ultrafiltrate flow rates and hemodiafilter types are unlikely to influence rezafungin CL_{TM} . No dosage adjustment of rezafungin is likely required for critically ill patients receiving CVVH.

© 2018 The Author(s)

Published by S. Karger AG, Basel

Introduction

The incidence of acute kidney injury (AKI) in an intensive care setting is between 20 and 50% [1]. Despite several technological advances in renal replacement therapies (RRT), the mortality rate remains in the range 50–60% for patients with AKI requiring RRT [2]. Sepsis is the most common cause of death in critically ill pa-

tients with AKI [3]. Systemic fungal infections represent a serious clinical complication in patients requiring RRT in the intensive care unit setting [4]. Some have suggested that inappropriate antibiotic dosing in these patients receiving continuous RRT (CRRT) is an important contributor to this high mortality rate [5, 6] and, similarly, inadequate antifungal dosing may lead to both treatment failure and resistance development [7, 8]. Echinocandins are considered the first-line antifungal therapy for invasive candidiasis, especially in critically ill patients [9].

Rezafungin is a novel long-acting echinocandin and its disposition during CRRT is unknown. Its high plasma protein binding (~97–99%) suggests that rezafungin would be poorly removed by RRT [10]. However, there is a potential for some transmembrane clearance (CL_{TM}) with contemporary hemodiafilters due to its relatively small volume of distribution (35 L) and molecular weight (1,285 Da). CRRT has the ability to remove relatively large drugs (MW 1,000–2,000 Da) compared to hemodialysis, as CRRT operates 24-h/day using high-permeability hemodiafilters [11, 12]. In addition, studies suggest that anidulafungin (with a similar chemical structure to rezafungin) binds to CRRT membranes [13]. The purpose of this ex vivo study is to quantify drug removal by CL_{TM} and CRRT circuit adsorption. As rezafungin is administered once weekly and therapeutic drug monitoring is not available, it is essential to understand the CRRT influence on rezafungin pharmacokinetics to ensure sufficient rezafungin exposure.

Materials and Methods

This study assessed drug adsorption and CL_{TM} using a continuous venovenous hemofiltration (CVVH) configuration. This validated ex vivo CVVH model [14–17] utilized 1 L of pH regulated, citrate-anti-coagulated bovine blood (Animal Technologies, Tyler, TX, USA). Using a Braun Diapact™ CRRT system (Braun, Bethlehem, PA, USA), 2 different hemodiafilters were tested. HF1400 (Polyarylethersulfone, Baxter Healthcare, Deerfield, IL, USA; surface area 1.4 m²) and the Multiflow-150 (AN69, Baxter Healthcare, Deerfield, IL, USA; surface area 1.5 m²) hemodiafilters were evaluated. New bovine blood, new hemodiafilters, and new CRRT tubing sets were used in each experiment. The blood was continuously stirred and heated to 37°C in a water bath during all experiments. Reconstituted rezafungin (Lot number AMU252277; Cidara Therapeutics, San Diego, CA, USA) was added to blood to achieve the final concentration of ~30 mg/L (approximating the plasma peak concentration following multiple once-weekly 400 mg doses [10]). Urea (Lot number 30K0221; Sigma, St. Louis, MO, USA) was used as a control and added to the blood to produce a blood urea nitrogen concentration of ~75 mg/dL.

Adsorption and Degradation

The purpose of the 1-h adsorption study was to determine if the drug adsorbs to the hemodiafilter or CRRT apparatus. Blood flow rates of 200 mL/min with an ultrafiltration rate (Q_{uf}) of 33 mL/min were used. This allowed rezafungin to have maximal contact with the membrane, both on the blood side and via convection through the hemodiafilter membrane. A closed system was developed to maintain a constant volume in the extracorporeal system. Ultrafiltrate was used as the replacement fluid that was returned to the blood as a post-filter replacement fluid to maintain a constant blood volume. The CRRT machine was primed with normal saline before the operation; consequently, the urea and rezafungin dilution caused by the residual priming solution was accounted for. Blood samples were collected from the pre-filter port at 0 (baseline), 5 (at which time mixing was complete), 10, 20, 30, and 60 min to assess adsorption over time. Previous studies have shown that membrane adsorption happens rapidly and is nearly complete in the first hour [18]. Each experiment was repeated 6 times with new hemodiafilters and tubing sets.

Degradation experiments ($n = 6$) were performed to ensure that the solutes were stable while placed in the 37°C blood for the 1-h experiments. One liter of bovine blood was prepared identically as stated above. Urea was also added in this experiment acting as a control because it is known to be stable at 37°C for an hour and does not bind to hemodiafilters and to the CRRT apparatus [19]. Blood samples were collected from the flask at 0 (baseline), 5, 10, 20, 30, and 60 min to detect degradation. Equations that were used to calculate dilution factor and adsorption are as follows:

$$\% \text{ Dilution factor} = \left(\frac{[\text{Urea}_{a0}] - [\text{Urea}_{ax}]}{[\text{Urea}_{a0}]} \right) \times 100 \quad (1)$$

where $[\text{Urea}_{a0}]$ = urea concentration in the pre-filter at time 0
 $[\text{Urea}_{ax}]$ = urea concentration in the pre-filter at time x

$$\% \text{ Adsorption} = \left(\frac{[C_5] - [C_{60}]}{[C_5]} \times 100 \right) - \text{Dilution factor} - \text{Degradation} \quad (2)$$

where $[C_5]$ = concentration of pre-filter rezafungin at 5 min
 $[C_{60}]$ = concentration of pre-filter rezafungin at 60 min.

Continuous Hemofiltration

The procedures for the CVVH study were similar to those described in our previous ex vivo studies [14, 15]. The CL_{TM} of urea and rezafungin were evaluated with different blood flow rates, Q_{uf} and hemodiafilters (Table 1). In a closed-loop system, the formed ultrafiltrate was returned to the blood as a post-filter replacement fluid downstream from the post-hemodiafilter blood sampling port. Figure 1 shows the schematic of the ex vivo post-filter replacement CVVH system. Pre- and post-hemodiafilter blood samples and ultrafiltrate samples were always collected concurrently. Samples were collected after 12 min when ultrafiltration rate was operated at 1 L/h. Then, ultrafiltration rate was changed to 2 L/h. Samples from these 3 ports were collected after 6 min when ultrafiltration rate was operated at 2 L/h. Lastly, ultrafiltration rate was changed to 3 L/h and samples were collected after 4 min. These sampling times were chosen to allow sufficient time for the ultrafiltrate to reflect the rezafungin concentrations arising from each of the different ultrafiltrate rates. Six experiments were conducted

Table 1. Q_b , Q_{uf} and types of hemodiafilters that were used for CVVH ex vivo study

Hemodiafilter: HF1400 ($n = 6$)			Hemodiafilter: multiflow-150 ($n = 6$)		
Q_b , mL/min	Q_{uf} , mL/min	sampling time, min	Q_b , mL/min	Q_{uf} , mL/min	sampling time, min
200	16.7	12	200	16.7	12
200	33.3	6	200	33.3	6
400	50.0	4	400	50.0	4

Q_b , blood flow rate; Q_{uf} , ultrafiltration rate.

Fig. 1. Schematic representation of the ex vivo post-filter replacement CVVH system.

for each hemodiafilter, and new hemodiafilters and CRRT apparatus were used for each experiment. Sieving coefficient (S_C) and CL_{TM} for post-filter replacement were calculated as follows [15]:

$$S_C = \frac{C_{uf}}{(C_a + C_v) / 2} \quad (3)$$

where C_{uf} = concentration in the ultrafiltrate

C_a = concentration of solute in the pre-filter

C_v = concentration of solute in the post-filter

$$CL_{TM} = (S_C \times Q_{uf}) \quad (4)$$

where S_C = observed sieving coefficient

Q_{uf} = ultrafiltration rate.

Sample Analysis

All blood samples were centrifuged at 3,000 rpm for 10 min. The plasma and ultrafiltrate samples were transferred to cryovials in duplicate. These samples were stored at -80°C until analysis.

Blood urea nitrogen concentrations were analyzed with Advia 1800 (Siemens Healthcare Diagnostic Inc., Tarrytown, NY, USA) with lower limit of quantification of 5 mg/dL. Rezafungin concentrations were measured by a Shimadzu HPLC coupled to an AB Sciex 5500 triple quadrupole mass spectrometer operating in selected reaction monitoring mode. The method employed triplicate standard calibrators prepared in ultrafiltrate using d_9 - rezafungin as internal standard and quantitation by analyte/internal standard area ratio versus concentration. For the degradation/adsorption samples, the calibration range was 1.00–50.0 $\mu\text{g/mL}$ and the accuracy, as measured by the percent of nominal, was 84.3–141%, and precision, as measured by percent coefficient of variation (%CV), was 1.88–12.8%. The analyses was quantified by a fit-for-purpose LC-MS/MS method aimed at determining if there was significant degradation or adsorption. The accuracy of 141% occurred at the lowest limit of quantitation, 1 $\mu\text{g/mL}$, and was deemed acceptable for this degradation/adsorption sample analysis, since most samples quantified well above this concentration (average 25 $\mu\text{g/mL}$). For the CVVH samples, the calibration range encompassed 0.500–50.0 $\mu\text{g/mL}$ and the accuracy was 70.8–118% with %CV of 4.37–8.65%.

Data Analysis

A power analysis calculation indicated that 6 experiments were required to detect a 25% of difference in the extent of rezafungin adsorption. Similarly, 6 CVVH experiments with each hemodiafilter were required to detect a 25% difference in rezafungin CL_{TM} between hemodiafilters (<http://powerandsamplesize.com/Calculators/Compare-2-Means/2-Sample-Equality>). Assumptions used in these calculations included a power of 90% and a standard deviation of 10% with a significance level of $p < 0.05$. Two-tailed, unpaired t test was used to compare differences between the 2 hemodiafilters, and analysis of variance was used to compare different Q_{uf} within each hemodiafilter type.

Results

No rezafungin degradation was observed after 1 h in blood at 37°C . The mean $\pm$ SD of rezafungin concentrations ($\mu\text{g/mL}$) were 28.4 ± 10 (at 5 min), 30.1 ± 7 (at 10 min), 32.6 ± 3 (at 20 min), 32.9 ± 3 (at 30 min), and 34.5 ± 2 (at 60 min). Neither rezafungin nor urea ad-

Fig. 2. Rezafungin concentration at different sampling times during the adsorption study (mean ± SD).

Fig. 3. Rezafungin transmembrane clearance during continuous hemofiltration (mean ± SD).

Table 2. Sieving coefficients of rezafungin and urea during CVVH experiments

Ultrafiltration rate, mL/min	HF1400 (<i>n</i> = 6, mean ± SD)		Multiflow-150 (<i>n</i> = 6, mean ± SD)	
	rezafungin	urea	rezafungin	urea
16.67	0	1.0±0.1	0	1.0±0.1
33.33	0	1.0±0.1	0	1.0±0.1
50	0	1.0±0.1	0	1.0±0.1

Both hemodiafilter types and 3 ultrafiltration rates did not influence the rezafungin clearance during CVVH experiments.

sorption was observed with either hemodiafilter type (Fig. 2). Hemodiafilter types (HF1400 $p = 0.5$; Multiflow-150 $p = 0.2$) and ultrafiltration rates did not influence the adsorption of rezafungin. As illustrated in Table 2, urea S_C consistently approximated 1 and urea CL_{TM} was dependent on ultrafiltrate production rate. Rezafungin S_C values were zero with 3 different Q_{uf} in both hemodiafilter types (Table 2). This ex vivo study indicates rezafungin is not cleared by CVVH either by CL_{TM} (Fig. 3) or by adsorption. The change in Q_{uf} and types of hemodiafilter did not influence the CL_{TM} ($p > 0.05$).

Discussion

No dosage adjustment for CRRT is necessary for currently marketed echinocandins (caspofungin, micafungin, anidulafungin) due to high protein binding

and predominant non-renal clearance. For instance, caspofungin's CL_{TM} by CVVH has been reported to be approximately 8 mL/h (1.8% of total clearance) and 5.9 mL/h (2.5% of total clearance) in continuous venovenous hemodialysis (CVVHD) [20]. A more recent study of caspofungin clearance by CVVH and continuous venovenous hemodiafiltration (CVVHDF) found a similarly negligible clearance by these therapies (48 and 42 mL/h, respectively) [21]. Likewise, micafungin CVVHDF clearance using the same AN69 membrane employed in our study was negligible in a clinical study of 10 patients [22]. In contrast, anidulafungin has conflicting data regarding adsorption. One report states that the influence of CRRT on anidulafungin elimination is negligible, since there was no anidulafungin adsorption to synthetic surfaces, and ultrafiltrate concentrations were below the assay limit of detection [23]. However, probable anidulafungin binding to CRRT membranes was observed in a clinical trial ($n = 10$) when pre- and

post-filter anidulafungin concentrations were compared, even though no drug was detected in the ultrafiltrate [13]. Our study findings did not detect rezafungin hemodiafilter binding, and found no measurable drug CL_{TM} .

Limitations of this study include the fact that we used bovine blood as the study matrix. Although bovine albumin occurs in approximately the same concentrations (~3 g/dL) as human serum albumin in critically ill patients receiving CRRT, bovine albumin is different than human albumin and protein binding may differ. However, comparisons of previous ex vivo studies using the same methods to in vivo CRRT trials of the same drug [16, 17] have shown good agreement in clearance estimates. Our findings of an SC not different from zero in the ex vivo model are very consistent with what is known about the extensive (97–99%) protein binding in humans receiving rezafungin [10].

Conclusion

Rezafungin is a novel, long-acting echinocandin, which is likely to be used in critically ill patients receiving CRRT. Based on the S_C observed in this ex vivo study, rezafungin is unlikely to be adsorbed nor cleared by any form of CRRT. Rezafungin is administered once weekly and dosage adjustment is not likely to be required for critically ill patients receiving CRRT.

Disclosure Statement

Dr. Mueller received grant funding from Cidara Therapeutics, Inc.

Funding Source

This investigator-initiated study was funded by Cidara Therapeutics, Inc.

References

- Case J, Khan S, Khalid R, Khan A: Epidemiology of acute kidney injury in the intensive care unit. *Crit Care Res Pract* 2013;2013:479730.
- Barbar SD, Binquet C, Monchi M, Bruyere R, Quenot JP: Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomized controlled trial. *Trials* 2014;15:270.
- Woodrow G, Turney JH: Cause of death in acute renal failure. *Nephrol Dial Transplant* 1992;7:230–234.
- Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O; AmarCand Study Group: Epidemiology, management, and risk factors for death of invasive *Candida* infections in critical care: a multicenter, prospective, observational study in France (2005–2006). *Crit Care Med* 2009;37:1612–1618.
- Kielstein JT, David S: Pro: Renal replacement trauma or Paracelsus 2.0. *Nephrol Dial Transplant* 2013;28:2728–2731;discussion 2731–2723.
- Lewis SJ, Mueller BA: Antibiotic dosing in critically ill patients receiving CRRT: underdosing is overprevalent. *Semin Dial* 2014;27:441–445.
- Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA: Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. *Int J Antimicrob Agents* 2012;39:1–10.
- Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Dimopoulos G: Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients Study. *Crit Care* 2015;19:33.
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD: Clinical practice guideline for the management of *Candidiasis*: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62:e1–e50.
- Sandison T, Ong V, Lee J, Thye D: Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. *Antimicrob Agents Chemother* 2017;61:pii:e01627–e01716.
- Chaijamorn W, Jitsurong A, Wiwattana-wongsa K, Wanakamane U, Dandecha P: Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. *Int J Antimicrob Agents* 2011;38:152–156.
- Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Sorgel F, Kinzig M, Mueller BA: Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. *Antimicrob Agents Chemother* 2014;58:1320–1326.
- Leitner JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Jager W, Bohmdorfer M, Thalhammer F: Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. *J Antimicrob Chemother* 2011;66:880–884.
- Lewis SJ, Switaj LA, Mueller BA: Tedizolid adsorption and transmembrane clearance during in vitro continuous renal replacement therapy. *Blood Purif* 2015;40:66–71.
- Chaijamorn W, Shaw AR, Lewis SJ, Mueller BA: Ex vivo ceftolozane/tazobactam clearance during continuous renal replacement therapy. *Blood Purif* 2017;44:16–23.
- Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. *Blood Purif* 2006;24:548–554.
- Vilay AM, Griot M, Depestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA: Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. *Crit Care Med* 2011;39:19–25.
- Clark WR, Macias WL, Molitoris BA, Wang NH: Plasma protein adsorption to highly permeable hemodialysis membranes. *Kidney Int* 1995;48:481–488.
- Marjani A: Effect of storage time and temperature on some serum analytes. *Internet J Lab Med* 2006;2:2.

- 20 Weiler S, Seger C, Pfisterer H, Stienecke E, Stippler F, Welte R, Joannidis M, Griesmacher A, Bellmann R: Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. *Antimicrob Agents Chemother* 2013;57:4053–4057.
- 21 Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Bruggemann RJ, Lefrant JY, Roberts JA: Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration. *Clin Pharmacokinet* 2017;56:1057–1068.
- 22 Vossen MG, Knafl D, Haidinger M, Lemmerer R, Unger M, Pferschy S, Lamm W, Maier-Salamon A, Jager W, Thalhammer F: Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients. *Antimicrob Agents Chemother* 2017;61:pii:e02425–e02516.
- 23 Aguilar G, Azanza JR, Carbonell JA, Ferrando C, Badenes R, Parra MA, Sadaba B, Navarro D, Puig J, Minana A, Garcia-Marquez C, Gencheva G, Gutierrez A, Marti FJ, Belda FJ: Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. *J Antimicrob Chemother* 2014;69:1620–1623.